Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 119

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis

Hollis, Chris, Pennant, Mary, Cuenca, José, Glazebrook, Cris, Kendall, Tim, Whittington, Craig, Stockton, Sarah, Larsson, Linnéa, Bunton, Penny, Dobson, Suzanne, Groom, Madeleine, Hedderly, Tammy, Heyman, Isobel, Jackson, Georgina M, Jackson, Stephen, Murphy, Tara, Rickards, Hugh, Robertson, Mary, Stern, Jeremy · 2016 · Health Technology Assessment

Abstract

Background: Tourette syndrome (TS) is a neurodevelopmental condition characterised by chronic motor and vocal tics affecting up to 1% of school-age children and young people and is associated with significant distress and psychosocial impairment. Objective: To conduct a systematic review of the benefits and risks of pharmacological, behavioural and physical interventions for tics in children and young people with TS (part 1) and to explore the experience of treatment and services from the perspective of young people with TS and their parents (part 2). Data Sources: For the systematic reviews (parts 1 and 2), mainstream bibliographic databases, The Cochrane Library, education, social care and grey literature databases were searched using subject headings and text words for tic* and Tourette* from database inception to January 2013. Review/research methods: For part 1, randomised controlled trials and controlled before-and-after studies of pharmacological, behavioural or physical interventions in children or young people (aged < 18 years) with TS or chronic tic disorder were included. Mixed studies and studies in adults were considered as supporting evidence. Risk of bias associated with each study was evaluated using the Cochrane tool. When there was sufficient data, random-effects meta-analysis was used to synthesize the evidence and the quality of evidence for each outcome was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach. For part 2, qualitative studies and survey literature conducted in populations of children/young people with TS or their carers or in health professionals with experience of treating TS were included in the qualitative review. Results were synthesized narratively. In addition, a national parent/carer survey was conducted via the Tourettes Action website. Participants included parents of children and young people with TS aged under 18 years. Participants (young people with TS aged 10–17 years) for the in-depth interviews were recruited via a national survey and specialist Tourettes clinics in the UK. Results: For part 1, 70 studies were included in the quantitative systematic review. The evidence suggested that for treating tics in children and young people with TS, antipsychotic drugs [standardised mean difference (SMD) –0.74, 95% confidence interval (CI) –1.08 to –0.41;n = 75] and noradrenergic agents [clonidine (Dixarit®, Boehringer Ingelheim) and guanfacine: SMD –0.72, 95% CI –1.03 to –0.40;n = 164] are effective in the short term. There was little difference among antipsychotics in terms of benefits, but adverse effect profiles do differ. Habit reversal training (HRT)/comprehensive behavioural intervention for tics (CBIT) was also shown to be effective (SMD –0.64, 95% CI –0.99 to –0.29;n = 133). For part 2, 295 parents/carers of children and young people with TS contributed useable survey data. Forty young people with TS participated in in-depth interviews. Four studies were in the qualitative review. Key themes were difficulties in accessing specialist care and behavioural interventions, delay in diagnosis, importance of anxiety and emotional symptoms, lack of provision of information to schools and inadequate information regarding medication and adverse effects. Limitations: The number and quality of clinical trials is low and this downgrades the strength of the evidence and conclusions. Conclusions: Antipsychotics, noradrenergic agents and HRT/CBIT are effective in reducing tics in children and young people with TS. The balance of benefits and harms favours the most commonly used medications: risperidone (Risperdal®, Janssen), clonidine and aripiprazole (Abilify®, Otsuka). Larger and better-conducted trials addressing important clinical uncertainties are required. Further research is needed into widening access to behavioural interventions through use of technology including mobile applications (‘apps’) and video consultation. Study registration: This study is registered as PROSPERO CRD42012002059. Funding: The National Institute for Health Research Health Technology Assessment programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta20040

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 206

  1. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders. DSM-5, 10.1176/appi.books.9780890425596 · DOI · Paper page
  2. World Health Organization (WHO), 1992, International Classification of Diseases and Health-Related Problems
  3. Robertson, 1989, The Gilles de la Tourette syndrome: the current status, Br J Psychiatry, 154, 147, 10.1192/bjp.154.2.147 · DOI · Paper page
  4. Robertson, 1994, Annotation: Gilles de la Tourette syndrome – an update, J Child Psychol Psychiatry, 35, 597, 10.1111/j.1469-7610.1994.tb01209.x · DOI
  5. Robertson, 1989, Self-injurious behaviour and the Gilles de la Tourette syndrome: a clinical study and review of the literature, Psychol Med, 19, 611, 10.1017/S0033291700024211 · DOI · Paper page
  6. Kurlan, 1996, Non–obscene complex socially inappropriate behavior in Tourette’s syndrome, J Neuropsychiatry Clin Neurosci, 8, 311, 10.1176/jnp.8.3.311 · DOI
  7. Robertson, 2013, Gilles de la Tourette Syndrome: The Current Status
  8. Robertson, 1999, The Tourette syndrome diagnostic confidence index: development and clinical associations, Neurology, 53, 2108, 10.1212/WNL.53.9.2108 · DOI · Paper page
  9. Robertson, 2012, The Gilles de la Tourette syndrome: the current status, Arch Dis Child Educ Pract Ed, 97, 166, 10.1136/archdischild-2011-300585 · DOI · Paper page
  10. Robertson, 2008, The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: The epidemiological and prevalence studies, J Psychosom Res, 65, 461, 10.1016/j.jpsychores.2008.03.006 · DOI · Paper page
  11. Robertson, 2008, The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: Tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes, J Psychosom Res, 65, 473, 10.1016/j.jpsychores.2008.03.007 · DOI
  12. Knight, 2012, Prevalence of tic disorders: a systematic review and meta-analysis, Pediatr Neurol, 47, 77, 10.1016/j.pediatrneurol.2012.05.002 · DOI · Paper page
  13. Ferrao, 2013, Tourette Syndrome, 50, 10.1093/med/9780199796267.003.0003 · DOI
  14. Cath, 2013, Tourette Syndrome, 74, 10.1093/med/9780199796267.003.0004 · DOI
  15. Khalifa, 2003, Prevalence of tic disorders and Tourette syndrome in a Swedish school population, Dev Med Child Neurol, 45, 315, 10.1111/j.1469-8749.2003.tb00402.x · doi:10.1111/j.1469-8749.2003.tb00402.x · Paper page
  16. Mol Debes, 2008, Validation of the presence of comorbidities in a Danish clinical cohort of children with Tourette syndrome, J Child Neurol, 23, 1017, 10.1177/0883073808316370 · DOI
  17. Scahill, 2013, Tourette Syndrome, 121, 10.1093/med/9780199796267.003.0006 · DOI
  18. Robertson, 2013, Tourette Syndrome, 361, 10.1093/med/9780199796267.003.0016 · DOI
  19. Fernandez, 2013, Tourette Syndrome, 137, 10.1093/med/9780199796267.003.0007 · DOI
  20. Pauls, 1994, Evidence against a genetic relationship between Tourette’s syndrome and anxiety, depression, panic and phobic disorders, Br J Psychiatry, 164, 215, 10.1192/bjp.164.2.215 · DOI
  21. Robertson, 1988, The psychopathology of the Gilles de la Tourette syndrome. A phenomenological analysis, Br J Psychiatry, 152, 383, 10.1192/bjp.152.3.383 · DOI · Paper page
  22. Robertson, 1988, Some personality variables in functional neurological disorders, Behav Neurol, 1, 23, 10.1155/1988/839812 · doi:10.1155/1988/839812
  23. Robertson, 1993, The psychopathology of Gilles de la Tourette’s syndrome. A controlled study, Br J Psychiatry, 162, 114, 10.1192/bjp.162.1.114 · DOI
  24. Robertson, 1997, Personality disorder and psychopathology in Tourette’s syndrome: a controlled study, Br J Psychiatry, 171, 283, 10.1192/bjp.171.3.283 · DOI
  25. Rickards, 2003, A controlled study of psychopathology and associated symptoms in Tourette syndrome, World J Biol Psychiatry, 4, 64, 10.3109/15622970309167953 · DOI
  26. Carter, 2000, Social and emotional adjustment in children affected with Gilles de la Tourette’s syndrome: associations with ADHD and family functioning. Attention Deficit Hyperactivity Disorder, J Child Psychol Psychiatry, 41, 215, 10.1017/S0021963099005156 · DOI · Paper page
  27. Robertson, 2002, Obsessive compulsive behaviour and depressive symptoms in young people with Tourette syndrome. A controlled study, Eur Child Adolesc Psychiatry, 11, 261, 10.1007/s00787-002-0301-3 · DOI
  28. Robertson, 2006, Behavioral and affective disorders in Tourette syndrome, Adv Neurol, 99, 39
  29. Sukhodolsky, 2003, Disruptive behavior in children with Tourette’s syndrome: association with ADHD comorbidity, tic severity, and functional impairment, J Am Acad Child Adolesc Psychiatry, 42, 98, 10.1097/00004583-200301000-00016 · DOI · Paper page
  30. Rizzo, 2007, Disentangling the effects of Tourette syndrome and attention deficit hyperactivity disorder on cognitive and behavioral phenotypes, Brain Dev, 29, 413, 10.1016/j.braindev.2006.12.003 · DOI
  31. Haddad, 2009, Adults with Tourette’s syndrome with and without attention deficit hyperactivity disorder, Acta Psychiatr Scand, 120, 299, 10.1111/j.1600-0447.2009.01398.x · DOI
  32. Elstner, 2001, Quality of Life (QOL) of patients with Gilles de la Tourette’s syndrome, Acta Psychiatr Scand, 103, 52, 10.1034/j.1600-0447.2001.00147.x · doi:10.1034/j.1600-0447.2001.00147.x · Paper page
  33. Cavanna, 2013, Disease-specific quality of life in young patients with tourette syndrome, Pediatr Neurol, 48, 111, 10.1016/j.pediatrneurol.2012.10.006 · DOI
  34. Eddy, 2012, The effects of comorbid obsessive–compulsive disorder and attention-deficit hyperactivity disorder on quality of life in tourette syndrome, J Neuropsychiatry Clin Neurosci, 24, 458, 10.1176/appi.neuropsych.11080181 · DOI · Paper page
  35. Robertson, 2012, A Family Guide to Tourette Syndrome, 171
  36. Sukhodolsky, 2013, Tourette Syndrome, 468, 10.1093/med/9780199796267.003.0021 · DOI
  37. Bawden, 1998, Peer relationship problems in children with Tourette’s disorder or diabetes mellitus, J Child Psychol Psychiatry, 39, 663, 10.1017/S0021963098002480 · DOI · Paper page
  38. Lee, 2007, Parenting stress and related factors in parents of children with Tourette syndrome, J Nurs Res, 15, 165, 10.1097/01.JNR.0000387612.85897.9a · DOI
  39. Cooper, 2003, Psychological morbidity and caregiver burden in parents of children with Tourette’s disorder and psychiatric comorbidity, J Am Acad Child Adolesc Psychiatry, 42, 1370, 10.1097/01.CHI.0000085751.71002.48 · DOI
  40. Robertson, 2003, Mental and Behavioral Dysfunction in Movement Disorders, 443, 10.1385/1-59259-326-7:443 · DOI
  41. Grados, 2008, Tourette Syndrome Association International Consortium for Genetics; Latent class analysis of Gilles de la Tourette syndrome using comorbidities: clinical and genetic implications, Biol Psychiatry, 64, 219, 10.1016/j.biopsych.2008.01.019 · DOI
  42. Cavanna, 2011, Dissecting the Gilles de la Tourette spectrum: a factor analytic study on 639 patients, J Neurol Neurosurg Psychiatry, 82, 1320, 10.1136/jnnp.2010.225029 · DOI
  43. Rodgers, 2014, Sex-related and non sex-related comorbidity subtypes of tic disorders: a latent class approach, Eur J Neurol, 21, 700, 10.1111/ene.12274 · DOI
  44. Robertson, 2000, Tourette syndrome, associated conditions and the complexities of treatment, Brain, 123, 425, 10.1093/brain/123.3.425 · DOI · Paper page
  45. Robertson, 2011, Gilles de la Tourette syndrome: the complexities of phenotype and treatment, Br J Hosp Med, 72, 100, 10.12968/hmed.2011.72.2.100 · DOI · Paper page
  46. Erenberg, 1987, The natural history of Tourette syndrome: a follow-up study, Ann Neurol, 22, 383, 10.1002/ana.410220317 · DOI · Paper page
  47. Leckman, 1998, Course of tic severity in Tourette syndrome: the first two decades, Pediatrics, 102, 14, 10.1542/peds.102.1.14 · DOI · Paper page
  48. Coffey, 2004, Reexamining tic persistence and tic-associated impairment in Tourette’s Disorder findings from a naturalistic follow-up study, J Nerv Ment Dis, 192, 776, 10.1097/01.nmd.0000144696.14555.c4 · DOI · Paper page
  49. Bloch, 2006, Fine-motor skill deficits in childhood predict adulthood tic severity and global psychosocial functioning in Tourette’s syndrome, J Child Psychol Psychiatry, 47, 551, 10.1111/j.1469-7610.2005.01561.x · DOI
  50. Pappert, 2003, Objective assessments of longitudinal outcome in Gilles de la Tourette’s syndrome, Neurology, 61, 936, 10.1212/01.WNL.0000086370.10186.7C · DOI · Paper page
  51. Lin, 2007, Psychosocial stress predicts future symptom severities in children and adolescents with Tourette syndrome and/or obsessive–compulsive disorder, J Child Psychol Psychiatry, 48, 157, 10.1111/j.1469-7610.2006.01687.x · DOI · Paper page
  52. Rizzo, 2012, Long term clinical course of Tourette syndrome, Brain Dev, 34, 667, 10.1016/j.braindev.2011.11.006 · DOI
  53. Ferenczi, 1921, Psychoanalytic observations on tic, Int J Psychoanal, 2, 1
  54. Mahler, 1943, A psychosomatic study of maladie des tics (Gilles de la Tourette’s Disease), Psychiatr Q, 17, 579, 10.1007/BF01561841 · doi:10.1007/bf01561841
  55. The Tourette Syndrome Association International Consortium for Genetics, 1999, A complete genome scan in sib-pairs affected with Gilles de la Tourette Syndrome, Am J Hum Gen, 65, 1428, 10.1086/302613 · DOI · Paper page
  56. Scharf, 2012, Prevalence of Tourette syndrome and chronic tics in the population-based Avon longitudinal study of parents and children cohort, J Am Acad Child Adolesc Psychiatry, 51, 192, 10.1016/j.jaac.2011.11.004 · DOI · Paper page
  57. Scharf, 2014, Genome-wide association study of Tourette’s syndrome, Mol Psychiatry, 18, 721, 10.1038/mp.2012.69 · DOI · Paper page
  58. Scharf, 2008, Lack of association between SLITRK1var321 and Tourette syndrome in a large family-based sample, Neurology, 70, 1495, 10.1212/01.wnl.0000296833.25484.bb · DOI
  59. Ercan-Sencicek, 2010, L-Histidine decarboxylase and Tourette’s syndrome, N Engl J Med, 362, 1901, 10.1056/NEJMoa0907006 · DOI · Paper page
  60. Swedo, 1998, Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases, Am J Psychiatry, 155, 264, 10.1176/ajp.155.2.264 · DOI · Paper page
  61. Murphy, 2004, Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive–compulsive disorder and tics, Biol Psychiatry, 55, 61, 10.1016/S0006-3223(03)00704-2 · DOI
  62. Kiessling, 1993, Antineuronal antibodies in movement disorders, Pediatrics, 92, 39, 10.1542/peds.92.1.39 · DOI · Paper page
  63. Kiessling, 1994, Antineuronal antibodies: tics and obsessive–compulsive symptoms, J Dev Behav Pediatr, 15, 421, 10.1097/00004703-199412000-00005 · DOI
  64. Muller, 2000, Increased anti-streptococcal antibodies in patients with Tourette’s syndrome, Psychiatry Res, 94, 43, 10.1016/S0165-1781(00)00125-6 · DOI
  65. Muller, 2001, Increased titers of antibodies against streptococcal M12 and M19 proteins in patients with Tourette’s syndrome, Psychiatry Res, 101, 187, 10.1016/S0165-1781(01)00215-3 · DOI
  66. Church, 2003, Tourette’s syndrome: a cross sectional study to examine the PANDAS hypothesis, J Neurol Neurosurg Psychiatry, 74, 602, 10.1136/jnnp.74.5.602 · DOI · Paper page
  67. Rizzo, 2006, Increased antistreptococcal antibody titers and anti-basal ganglia antibodies in patients with Tourette syndrome: Controlled cross-sectional study, J Child Neurol, 21, 747, 10.1177/08830738060210091001 · DOI
  68. Peterson, 2000, Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in tic, obsessive–compulsive, and attention deficit/hyperactivity disorders, Arch Gen Psychiatry, 57, 364, 10.1001/archpsyc.57.4.364 · DOI · Paper page
  69. Singer, 2008, Serial immune markers do not correlate with clinical exacerbations in pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, Pediatrics, 121, 1198, 10.1542/peds.2007-2658 · DOI
  70. Murphy, 2013, Tourette Syndrome, 168, 10.1093/med/9780199796267.003.0009 · DOI
  71. Rhee, 2012, Lyme disease and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an overview, Int J Gen Med, 5, 163, 10.2147/IJGM.S24212 · DOI
  72. Riedel, 1998, Lyme disease presenting as Tourette’s syndrome, Lancet, 351, 418, 10.1016/S0140-6736(05)78357-4 · DOI
  73. Court, 2013, One Bite Changed My Life Forever
  74. Editorial, 2013, Yours Magazine, 20
  75. Leckman, 2003, Mental and Behavioral Dysfunction in Movement Disorders, 467, 10.1385/1-59259-326-7:467 · doi:10.1385/1-59259-326-7:467
  76. Pasamanick, 1956, A study of the association of prenatal and paranatal factors with the development of tics in children; a preliminary investigation, J Pediatr, 48, 596, 10.1016/S0022-3476(56)80095-4 · DOI
  77. Burd, 1999, Prenatal and perinatal risk factors for Tourette disorder, J Perinat Med, 27, 295, 10.1515/jpm.1999.042 · DOI
  78. Mathews, 2006, Association between maternal smoking and increased symptom severity in Tourette’s syndrome, Am J Psychiatry, 163, 1066, 10.1176/ajp.2006.163.6.1066 · DOI
  79. Hoekstra, 2013, Tourette Syndrome, 156, 10.1093/med/9780199796267.003.0008 · DOI
  80. Murphy, 2013, Tourette Syndrome, 439, 10.1093/med/9780199796267.003.0020 · DOI
  81. Mueller, 2006, Enhanced cognitive control in young people with Tourette’s syndrome, Curr Biol, 16, 570, 10.1016/j.cub.2006.01.064 · DOI · Paper page
  82. Jackson, 2011, Compensatory neural reorganization in Tourette syndrome, Curr Biol, 21, 580, 10.1016/j.cub.2011.02.047 · DOI
  83. Greene, 2013, Tourette Syndrome, 238, 10.1093/med/9780199796267.003.0012 · DOI
  84. Sandor, 2013, Tourette’s with Dignity. Don’t Tic Me Off. The Youthdale Series
  85. Eddy, 2011, Quality of life in young people with Tourette syndrome: a controlled study, J Neurol, 258, 291, 10.1007/s00415-010-5754-6 · DOI · Paper page
  86. Storch, 2007, Quality of life in youth with Tourette’s syndrome and chronic tic disorder, J Clin Child Adolesc Psychol, 36, 217, 10.1080/15374410701279545 · DOI · Paper page
  87. Burd, 1992, Tourette Syndrome and learning-disabilities, J Learn Disabil, 25, 598, 10.1177/002221949202500909 · DOI
  88. Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
  89. Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, J Clin Epidemiol, 64, 380, 10.1016/j.jclinepi.2010.09.011 · DOI · Paper page
  90. Shapiro, 1968, Treatment of Gilles de la Tourette’s Syndrome with haloperidol, Br J Psychiatry, 114, 345, 10.1192/bjp.114.508.345 · DOI
  91. Harris, 2006, Tic disorders: neural circuits, neurochemistry, and neuroimmunology, J Child Neurol, 21, 678, 10.1177/08830738060210080901 · DOI
  92. Pringsheim, 2011, Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders, Cochrane Database Syst Rev, 4, CD007990, 10.1002/14651858.cd007990.pub2 · DOI · Paper page
  93. Waldon, 2013, Trials of pharmacological interventions for Tourette syndrome: a systematic review, Behav Neurol, 26, 265, 10.1155/2013/626410 · DOI
  94. Roessner, 2013, Pharmacological treatment of tic disorders and Tourette Syndrome, Neuropharmacology, 68, 143, 10.1016/j.neuropharm.2012.05.043 · DOI
  95. Sallee, 1997, Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder, Am J Psychiatry, 154, 1057, 10.1176/ajp.154.8.1057 · DOI · Paper page
  96. Shapiro, 1989, Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome, Arch Gen Psychiatry, 46, 722, 10.1001/archpsyc.1989.01810080052006 · DOI · Paper page
  97. Shapiro, 1984, Controlled study of pimozide vs. placebo in Tourette’s syndrome, J Am Acad Child Psychiatry, 23, 161, 10.1097/00004583-198403000-00007 · DOI · Paper page
  98. Dion, 2002, Risperidone in the treatment of Tourette syndrome: A double-blind, placebo-controlled trial, J Clin Psychopharmacol, 22, 31, 10.1097/00004714-200202000-00006 · DOI · Paper page
  99. Sallee, 2000, Ziprasidone treatment of children and adolescents with Tourette’s syndrome: A pilot study, J Am Acad Child Adolesc Psychiatry, 39, 292, 10.1097/00004583-200003000-00010 · DOI · Paper page
  100. Gilbert, 2004, Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial, J Am Acad Child Adolesc Psychiatry, 43, 206, 10.1097/00004583-200402000-00017 · DOI
  101. Bruggeman, 2001, Risperidone versus pimozide in Tourette’s disorder: A comparative double-blind parallel-group study, J Clin Psychiatry, 62, 50, 10.4088/JCP.v62n0111 · DOI · Paper page
  102. Ross, 1978, A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette’s syndrome, Am J Psychiatry, 135, 585, 10.1176/ajp.135.5.585 · DOI
  103. Liu, 2011, A multicenter controlled study on aripiprazole treatment for children with Tourette syndrome in China, Zhonghua Er Ke Za Zhi, 49, 572
  104. Yoo, 2011, Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders, Eur Child Adolesc Psychiatry, 20, 127, 10.1007/s00787-010-0154-0 · DOI
  105. Gulisano, 2011, Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome, Neurol Sci, 32, 1213, 10.1007/s10072-011-0678-1 · DOI
  106. Ji, 2005, Olanzapine for treatment of Tourette syndrome: a double-blind randomised controlled trial, Chin J Clin Rehabil, 9, 66
  107. Fulop, 1987, ECG changes during haloperidol and pimozide treatment of Tourette’s disorder, Am J Psychiatry, 144, 673, 10.1176/ajp.144.5.673 · DOI
  108. Flockhart, 2000, Studies on the mechanism of a fatal clarithromycin–pimozide interaction in a patient with Tourette syndrome, J Clin Psychopharmacol, 20, 317, 10.1097/00004714-200006000-00005 · DOI
  109. Goetz, 1987, Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods, Ann Neurol, 21, 307, 10.1002/ana.410210313 · DOI · Paper page
  110. Singer, 1995, The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine, Pediatrics, 95, 74, 10.1542/peds.95.1.74 · DOI · Paper page
  111. Leckman, 1991, Clonidine treatment of Gilles de la Tourette’s syndrome, Arch Gen Psychiatry, 48, 324, 10.1001/archpsyc.1991.01810280040006 · DOI · Paper page
  112. Du, 2008, Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders, Aust N Z J Psychiatry, 42, 807, 10.1080/00048670802277222 · DOI · Paper page
  113. Zhong, 2007, Randomized double-blind controlled study on treatment of tic disorders in children with transcutaneous patch of clonidine, Zhonghua Er Ke Za Zhi, 45, 785
  114. Gancher, 1990, Treatment of Tourette’s syndrome with transdermal clonidine: a pilot study, J Neuropsychiatry Clin Neurosci, 2, 66, 10.1176/jnp.2.1.66 · DOI
  115. Scahill, 2001, A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder, Am J Psychiatry, 158, 1067, 10.1176/appi.ajp.158.7.1067 · DOI · Paper page
  116. Cummings, 2002, Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study, Clin Neuropharmacol, 25, 325, 10.1097/00002826-200211000-00009 · DOI
  117. Allen, 2005, Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders, Neurology, 65, 1941, 10.1212/01.wnl.0000188869.58300.a7 · DOI · Paper page
  118. Gadow, 1992, Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings, J Am Acad Child Adolesc Psychiatry, 31, 462, 10.1097/00004583-199205000-00012 · DOI
  119. Gadow, 2007, Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder, J Am Acad Child Adolesc Psychiatry, 46, 840, 10.1097/chi.0b013e31805c0860 · DOI
  120. Castellanos, 1997, Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: Effects of stimulant and dose, J Am Acad Child Adolesc Psychiatry, 36, 589, 10.1097/00004583-199705000-00008 · DOI · Paper page
  121. Lyon, 2010, Testing tic suppression: Comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette’s disorder, J Child Adolesc Psychopharmacol, 20, 283, 10.1089/cap.2010.0032 · DOI · Paper page
  122. Ondo, 2006, Topiramate in essential tremor: a double-blind, placebo-controlled trial, Neurology, 66, 672, 10.1212/01.wnl.0000200779.03748.0f · DOI · Paper page
  123. Smith-Hicks, 2007, A double blind randomized placebo control trial of levetiracetam in Tourette syndrome, Mov Disord, 22, 1764, 10.1002/mds.21615 · DOI · Paper page
  124. Awaad, 2009, Levetiracetam in Tourette syndrome: a randomized double blind, placebo controlled study, J Pediatr Neurol, 7, 257
  125. Jankovic, 2010, A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome, J Neurol Neurosurg Psychiatry, 81, 70, 10.1136/jnnp.2009.185348 · DOI · Paper page
  126. Feigin, 1996, A controlled trial of deprenyl in children with Tourette’s syndrome and attention deficit hyperactivity disorder, Neurology, 46, 965, 10.1212/WNL.46.4.965 · DOI · Paper page
  127. Zanettini, 2007, Valvular heart disease and the use of dopamine agonists for Parkinson’s disease, N Engl J Med, 356, 39, 10.1056/NEJMoa054830 · DOI · Paper page
  128. Schade, 2007, Dopamine agonists and the risk of cardiac-valve regurgitation, N Engl J Med, 356, 29, 10.1056/NEJMoa062222 · DOI · Paper page
  129. Gilbert, 2000, Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial, Neurology, 54, 1310, 10.1212/WNL.54.6.1310 · DOI
  130. Gilbert, 2003, Tic reduction with pergolide in a randomized controlled trial in children, Neurology, 60, 606, 10.1212/01.WNL.0000044058.64647.7E · DOI · Paper page
  131. Kurlan, 2012, A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette’s syndrome, Mov Disord, 27, 775, 10.1002/mds.24919 · DOI · Paper page
  132. Nicolson, 2005, A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette’s disorder, J Am Acad Child Adolesc Psychiatry, 44, 640, 10.1097/01.chi.0000163279.39598.44 · DOI · Paper page
  133. Singer, 2001, Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial, Neurology, 56, 599, 10.1212/WNL.56.5.599 · DOI
  134. Spencer, 2002, A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder, Arch Gen Psychiatry, 59, 649, 10.1001/archpsyc.59.7.649 · DOI · Paper page
  135. Rickards, 2012, Treatment practices in Tourette syndrome: the European perspective, Eur J Paediatr Neurol, 16, 361, 10.1016/j.ejpn.2011.12.001 · DOI
  136. Kurlan, 1993, A pilot controlled study of fluoxetine for obsessive–compulsive symptoms in children with Tourette’s syndrome, Clin Neuropharmacol, 16, 167, 10.1097/00002826-199304000-00009 · DOI
  137. Scahill, 1997, Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study, J Child Adolesc Psychopharmacol, 7, 75, 10.1089/cap.1997.7.75 · DOI
  138. Sanberg, 1998, Treatment of Tourette’s syndrome with mecamylamine, Lancet, 352, 705, 10.1016/S0140-6736(05)60822-7 · DOI
  139. Silver, 2001, Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for tourette’s disorder, J Am Acad Child Adolesc Psychiatry, 40, 1103, 10.1097/00004583-200109000-00020 · DOI · Paper page
  140. Howson, 2004, Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome, Eur Psychiatry, 19, 102, 10.1016/j.eurpsy.2003.11.002 · DOI
  141. Gabbay, 2012, A double-blind, placebo-controlled trial of omega-3 fatty acids in Tourette’s disorder, Pediatrics, 129, e1493, 10.1542/peds.2011-3384 · DOI
  142. Gaffney, 2002, Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome, J Am Acad Child Adolesc Psychiatry, 41, 330, 10.1097/00004583-200203000-00013 · DOI · Paper page
  143. George, 1993, Fluvoxamine and sulpiride in comorbid obsessive–compulsive disorder and Gilles de la Tourette Syndrome, Hum Psychopharmacol, 8, 327, 10.1002/hup.470080505 · DOI
  144. Hedderick, 2009, Double-Blind, Crossover Study of Clonidine and Levetiracetam in Tourette Syndrome, Pediatric Neurology, 40, 420, 10.1016/j.pediatrneurol.2008.12.014 · DOI · Paper page
  145. Kang, 2009, Efficacy of clonidine transdermal patch for treatment of Tourette’s syndrome in children, Zhongguo Dang Dai Er Ke Za Zhi, 11, 537
  146. Carr, 1995, Competing responses for the treatment of Tourette syndrome and tic disorders, Behav Res Ther, 33, 455, 10.1016/0005-7967(94)00066-S · DOI
  147. Ganos, 2012, Are premonitory urges a prerequisite of tic inhibition in Gilles de la Tourette syndrome?, J Neurol Neurosurg Psychiatry, 83, 975, 10.1136/jnnp-2012-303033 · DOI
  148. Verdellen, 2011, European clinical guidelines for Tourette Syndrome and other tic disorders. Part III: behavioural and psychosocial interventions, Eur Child Adolesc Psychiatry, 20, 197, 10.1007/s00787-011-0167-3 · DOI · Paper page
  149. Steeves, 2012, Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation, Can J Psychiatry, 57, 144, 10.1177/070674371205700303 · DOI · Paper page
  150. Hoogduim, 1998, Exposure and response prevention in the treatment of Gilles de la Tourette’s Syndrome: four case studies, Clin Psychol Psychother, 4, 125, 10.1002/(SICI)1099-0879(199706)4:2<125::AID-CPP125>3.0.CO;2-Z · DOI
  151. Yates, 1958, The application of learning theory to the treatment of tics, J Abnorm Soc Psychol, 56, 175, 10.1037/h0040699 · DOI · Paper page
  152. Peterson, 1992, An evaluation of behavioral treatments for Tourette syndrome, Behav Res Ther, 30, 167, 10.1016/0005-7967(92)90140-C · DOI
  153. Sukhodolsky, 2004, Cognitive-behavioral therapy for anger in children and adolescents: a meta-analysis, Aggress Violent Beh, 9, 247, 10.1016/j.avb.2003.08.005 · doi:10.1016/j.avb.2003.08.005 · Paper page
  154. Scahill, 2006, Randomized trial of parent management training in children with tic disorders and disruptive behavior, J Child Neurol, 21, 650, 10.1177/08830738060210080201 · DOI · Paper page
  155. Barkley, 2002, Psychosocial treatments for attention-deficit/hyperactivity disorder in children, J Clin Psychiatry, 63, 36
  156. Wilhelm, 2012, Randomized trial of behavior therapy for adults with Tourette syndrome, Arch Gen Psychiatry, 69, 795, 10.1001/archgenpsychiatry.2011.1528 · DOI · Paper page
  157. Wilhelm, 2003, Habit reversal versus supportive psychotherapy for Tourette’s disorder: a randomized controlled trial, Am J Psychiatry, 160, 1175, 10.1176/appi.ajp.160.6.1175 · DOI · Paper page
  158. Azrin, 1990, Treatment of Tourette Syndrome by habit reversal: a waiting-list control group comparison, Behav Ther, 21, 305, 10.1016/S0005-7894(05)80333-8 · DOI · Paper page
  159. Azrin, 1980, Habit reversal vs negative practice treatment of nervous tics, Behav Ther, 11, 169, 10.1016/S0005-7894(80)80017-7 · DOI · Paper page
  160. Verdellen, 2004, Exposure with response prevention versus habit reversal in Tourette’s syndrome: A controlled study, Behav Res Ther, 42, 501, 10.1016/S0005-7967(03)00154-2 · DOI · Paper page
  161. Himle, 2012, A randomized pilot trial comparing videoconference versus face-to-face delivery of behavior therapy for childhood tic disorders, Behav Res Ther, 50, 565, 10.1016/j.brat.2012.05.009 · DOI · Paper page
  162. Bergin, 1998, Relaxation therapy in Tourette syndrome: a pilot study, Pediatr Neurol, 18, 136, 10.1016/S0887-8994(97)00200-2 · DOI
  163. Sukhodolsky, 2009, Randomized trial of anger control training for adolescents with Tourette’s syndrome and disruptive behavior, J Am Acad Child Adolesc Psychiatry, 48, 413, 10.1097/CHI.0b013e3181985050 · DOI · Paper page
  164. Woods, 2011, Behavior therapy for tics in children: acute and long-term effects on psychiatric and psychosocial functioning, J Child Neurol, 26, 858, 10.1177/0883073810397046 · DOI · Paper page
  165. Anderson, 2006, Surgery insight: Deep brain stimulation for movement disorders. Nature clinical practice, Neurology, 2, 310, 10.1038/ncpneuro0193 · DOI
  166. Cavanna, 2011, An approach to deep brain stimulation for severe treatment-refractory Tourette syndrome: the UK perspective, Br J Neurosurg, 25, 38, 10.3109/02688697.2010.534200 · DOI
  167. Lyons, 2011, Deep brain stimulation: current and future clinical applications, Mayo Clinic Proc, 86, 662, 10.4065/mcp.2011.0045 · DOI · Paper page
  168. Vandewalle, 1999, Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus, Lancet, 353, 724, 10.1016/S0140-6736(98)05964-9 · DOI · Paper page
  169. Piedad, 2012, What patients with Gilles de la tourette syndrome should be treated with deep brain stimulation and what is the best target?, Neurosurgery, 71, 173, 10.1227/NEU.0b013e3182535a00 · DOI
  170. Hariz, 2010, Gilles de la Tourette syndrome and deep brain stimulation, Eur J Neurosci, 32, 1128, 10.1111/j.1460-9568.2010.07415.x · DOI
  171. Mink, 2006, Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome, Mov Disord, 21, 1831, 10.1002/mds.21039 · DOI · Paper page
  172. Muller-Vahl, 2011, European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation, Eur Child Adolesc Psychiatry, 20, 209, 10.1007/s00787-011-0166-4 · DOI
  173. Edwards, 2008, Clinical applications of transcranial magnetic stimulation in patients with movement disorders, Lancet Neurol, 7, 827, 10.1016/S1474-4422(08)70190-X · DOI
  174. Gilbert, 2004, Should transcranial magnetic stimulation research in children be considered minimal risk?, Clin Neurophysiol, 115, 1730, 10.1016/j.clinph.2003.10.037 · DOI
  175. Hoekstra, 2002, Is Tourette’s syndrome an autoimmune disease?, Mol Psychiatry, 7, 437, 10.1038/sj.mp.4000972 · DOI
  176. Hoekstra, 2004, Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study, J Clin Psychiatry, 65, 537, 10.4088/JCP.v65n0413 · DOI
  177. Kivity, 2010, Evidence for the use of intravenous immunoglobulins – a review of the literature, Clin Rev Allergy Immunol, 38, 201, 10.1007/s12016-009-8155-9 · DOI
  178. Anton, Botulinum toxins: Adverse effects, Adverse Drug React Bull, 1027, 10.1097/FAD.0b013e328346f575 · doi:10.1097/fad.0b013e328346f575
  179. Bloch, 2008, Emerging treatment for Tourette’s disorder, Curr Psychiatry Rep, 10, 323, 10.1007/s11920-008-0052-z · DOI
  180. Berardelli, 1997, Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Ital Soc Neurol, 18, 261, 10.1007/BF02083302 · DOI
  181. Simpson, 2008, Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology, 70, 1699, 10.1212/01.wnl.0000311389.26145.95 · DOI · Paper page
  182. Cui, 2009, Acupuncture for Gilles de la Tourette’s syndrome, Cochrane Database Syst Rev, CD007832, 10.1002/14651858.cd007832 · DOI
  183. Ackermans, 2011, Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome, Brain, 134, 832, 10.1093/brain/awq380 · DOI · Paper page
  184. Welter, 2008, Internal pallidal and thalamic stimulation in patients with Tourette syndrome, Arch Neurol, 65, 952, 10.1001/archneur.65.7.952 · DOI · Paper page
  185. Maciunas, 2007, Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome, J Neurosurg, 107, 1004, 10.3171/JNS-07/11/1004 · DOI · Paper page
  186. Orth, 2005, Subthreshold rTMS over pre-motor cortex has no effect on tics in patients with Gilles de la Tourette syndrome, Clin Neurophysiol, 116, 764, 10.1016/j.clinph.2004.10.003 · DOI · Paper page
  187. Chae, 2004, A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette’s syndrome, Cogn Behav Neurol, 17, 109, 10.1097/01.wnn.0000116253.78804.3a · DOI
  188. Munchau, 2002, Repetitive transcranial magnetic stimulation for Tourette syndrome, Neurology, 59, 1789, 10.1212/01.WNL.0000036615.25044.50 · DOI
  189. Marras, 2001, Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial, Neurology, 56, 605, 10.1212/WNL.56.5.605 · DOI · Paper page
  190. Chi, 2003, Clinical study on treatment of tourette’s syndrome with acupuncture-Chinese herbs combination, Journal of Acupuncture and Tuina Science, 1, 15, 10.1007/BF02845419 · doi:10.1007/bf02845419
  191. Kurlan, 1998, Tourette’s syndrome and ‘PANDAS’: will the relation bear out? Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, Neurology, 50, 1530, 10.1212/WNL.50.6.1530 · DOI
  192. Kurlan, 2004, The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) etiology for tics and obsessive–compulsive symptoms: hypothesis or entity? Practical considerations for the clinician, Pediatrics, 113, 883, 10.1542/peds.113.4.883 · DOI · Paper page
  193. Garvey, 1999, A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections, Biol Psychiatry, 45, 1564, 10.1016/S0006-3223(99)00020-7 · DOI · Paper page
  194. Elliott, 2013, Talking About Medicines (Tabs): Involving Children and Young People With Chronic Illness in Managing Their Medicines. Final Report
  195. Rivera-Navarro, 2009, The diagnosis of Tourette’s Syndrome: communication and impact, Clin Child Psychol Psychiatry, 14, 13, 10.1177/1359104508100127 · DOI
  196. Mol Debes, 2008, Limited knowledge of Tourette syndrome causes delay in diagnosis, Neuropediatrics, 39, 101, 10.1055/s-2008-1081457 · doi:10.1055/s-2008-1081457
  197. Kompoliti, 2006, Gilles de la Tourette syndrome: Patient’s knowledge and concern of adverse effects, Mov Disord, 21, 248, 10.1002/mds.20680 · doi:10.1002/mds.20680
  198. Woods, 2010, Behavior Therapy for Tourette’s Disorder: Utilization in a Community Sample and an Emerging Area of Practice for Psychologists, Prof Psychol Res Pr, 41, 518, 10.1037/a0021709 · DOI · Paper page
  199. Conelea, 2011, Exploring the impact of chronic tic disorders on youth: results from the Tourette Syndrome Impact Survey, Child Psychiatry Hum Dev, 42, 219, 10.1007/s10578-010-0211-4 · DOI · Paper page
  200. Leckman, 1989, The Yale Global Tic Severity Scale – Initial testing of a clinician-rated scale of tic severity, J Am Acad Child Adolesc Psychiatry, 28, 566, 10.1097/00004583-198907000-00015 · DOI · Paper page

200 of 206 shown

Cited by

See all 119

Metadata

Authors
Hollis, C., Pennant, M., Cuenca, J., Glazebrook, C., Kendall, T., Whittington, C., Stockton, S., Larsson, L., Bunton, P., Dobson, S., Groom, M., Hedderly, T., Heyman, I., Jackson, G. M., Jackson, S., Murphy, T., Rickards, H., Robertson, M., & Stern, J.
Venue
Health Technology Assessment
Published
2016-01
Volume
20
Issue
4
Pages
1-450
ISSN
  • 1366-5278
  • 2046-4924
Cited by
119
References
14
Language
en
Funders
Health Technology Assessment programme (10/142/01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.